Title : The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem.

Pub. Date : 2018 Sep

PMID : 30178440






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In addition, since zolpidem is metabolized at a high rate by CYP3A4, the effect of CYP2C9*3 allele on the pharmacokinetics of zolpidem was also observed in the condition where CYP3A4 was sufficiently inhibited by the steady-state concentration of clarithromycin, a potent CYP3A4 inhibitor. Clarithromycin cytochrome P450 family 3 subfamily A member 4 Homo sapiens
2 In addition, since zolpidem is metabolized at a high rate by CYP3A4, the effect of CYP2C9*3 allele on the pharmacokinetics of zolpidem was also observed in the condition where CYP3A4 was sufficiently inhibited by the steady-state concentration of clarithromycin, a potent CYP3A4 inhibitor. Clarithromycin cytochrome P450 family 3 subfamily A member 4 Homo sapiens
3 In addition, since zolpidem is metabolized at a high rate by CYP3A4, the effect of CYP2C9*3 allele on the pharmacokinetics of zolpidem was also observed in the condition where CYP3A4 was sufficiently inhibited by the steady-state concentration of clarithromycin, a potent CYP3A4 inhibitor. Clarithromycin cytochrome P450 family 3 subfamily A member 4 Homo sapiens
4 Even with the potent CYP3A4 inhibitor clarithromycin present at steady-state concentrations, there were no significant differences in the exposure of zolpidem, except for elimination half-life (t1/2). Clarithromycin cytochrome P450 family 3 subfamily A member 4 Homo sapiens